血漿分画市場-世界の産業規模、シェア、動向、機会、予測、製品別、用途別、地域別、競合別、2020～2030年

血漿分画の世界市場規模は2024年に257億8,000万米ドル、2030年には368億2,000万米ドルに達し、CAGR 6.32%で成長すると予測されています。

この成長を牽引しているのは、血友病、原発性免疫不全症、ギラン・バレー症候群や慢性炎症性脱髄性多発神経炎などの神経疾患を含む慢性疾患や希少疾患の管理における血漿由来療法への依存度の高まりです。高齢者の増加と免疫関連疾患と出血性疾患の有病率の増加が、免疫グロブリン、アルブミン、凝固因子などの血漿ベースの製品に対する安定した需要に寄与しています。

特に新興経済諸国における血漿採取インフラの継続的な開発が、市場拡大をさらに後押ししています。しかし、製造コストの高さ、複雑な規制、製造期間の長期化といった課題が、拡大性の妨げとなっています。さらに、遺伝子組換え製剤や生物製剤との競合が、従来型血漿ベースの治療法に対する脅威となっています。

主要市場促進要因

ヘルスケア産業の成長

主要市場課題

限られた血漿供給と献血インフラ

主要市場動向

自己免疫疾患と神経疾患における血漿分画の使用の増加

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界の血漿分画市場に与える影響

第5章 世界の血漿分画市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別（アルブミン、免疫グロブリン、凝固因子、プロテアーゼ阻害剤、その他）
  • 用途別（神経学、血液学、腫瘍学、免疫学、その他）
  • 地域別
  • 企業別（2024年）
• 市場マップ

第6章 北米の血漿分画市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州の血漿分画市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋の血漿分画市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米の血漿分画市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの血漿分画市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収
• 製品上市

第13章 混乱：紛争、パンデミック、貿易障壁

第14章 世界の血漿分画市場：SWOT分析

第15章 ポーターのファイブフォース分析

• 産業内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第16章 競合情勢

• Grifols S.A.
• Octapharma AG
• Intas Pharmaceuticals Ltd
• LFB S.A.
• Takeda Pharmaceutical Company Limited
• CSL Limited
• BIoTest AG
• Kedrion S.p.A
• Bio Products Laboratory Ltd.
• Bharat Serums and Vaccines Limited

第17章 戦略的提言

第18章 調査会社について・免責事項

The Global Plasma Fractionation Market was valued at USD 25.78 Billion in 2024 and is projected to reach USD 36.82 Billion by 2030, growing at a CAGR of 6.32%. This growth is driven by the increasing reliance on plasma-derived therapies to manage chronic and rare conditions, including hemophilia, primary immunodeficiency disorders, and neurological diseases like Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy. The expanding elderly population and a higher prevalence of immune-related and bleeding disorders are contributing to the steady demand for plasma-based products such as immunoglobulins, albumin, and clotting factors.

The continuous development of plasma collection infrastructure, especially across emerging economies, is further supporting market expansion. However, challenges such as high production costs, complex regulations, and prolonged manufacturing timelines hinder scalability. Additionally, competition from recombinant and biologic alternatives presents a threat to traditional plasma-based therapies.

Key Market Drivers

Growth in Healthcare Industry

The consistent expansion of the global healthcare industry is a fundamental driver of the plasma fractionation market. Generating more than USD 4 trillion annually, the industry sees strong contributions from pharmaceuticals and biotechnology at nearly USD 850 billion, and from diagnostics and medical technology at over USD 400 billion. These investments, along with improved infrastructure and wider access to services, are supporting the increasing use of plasma-derived treatments for conditions like immunodeficiencies, hemophilia, liver disease, and trauma-related bleeding.

By 2026, hospitals worldwide are projected to number 215,977, with growth mainly concentrated in the Far East & China and the Middle East & Africa. The expansion of hospitals and specialty clinics-especially in developing regions-is enhancing plasma collection and processing capabilities. This development is enabling a more stable global supply of fractionated products, while the rise in outpatient and personalized care models is also accelerating the adoption of these therapies.

Key Market Challenges

Limited Plasma Supply & Donation Infrastructure

A critical challenge in the plasma fractionation market is the limited availability of plasma due to underdeveloped donation systems. Plasma serves as the raw material for essential therapies such as immunoglobulins and clotting factors, yet its supply remains constrained by low donor participation and inconsistent infrastructure-particularly in lower-income countries.

In many regions, plasma collection systems are sparse or nonexistent, leading to an imbalance between growing therapeutic demand and available plasma volumes. Plasmapheresis procedures require specialized equipment, skilled staff, and time, which further limits capacity and scalability, especially in resource-limited settings.

Key Market Trends

Increasing Use of Plasma Fractionation in Autoimmune and Neurological Disorders

With over 57 million liters of plasma used annually to produce critical treatments, demand for plasma-derived therapies continues to climb-especially in managing autoimmune and neurological disorders. Conditions such as CIDP, Guillain-Barre syndrome, multiple sclerosis, and myasthenia gravis are increasingly treated with fractionated products, particularly intravenous immunoglobulin (IVIG), due to its immunomodulatory benefits.

IVIG has become a standard therapy for many of these conditions, backed by its inclusion in treatment guidelines and proven efficacy. Moreover, its use is expanding beyond conventional applications to address refractory cases and relapse prevention, reinforcing its growing role in neurology and chronic care management.

Key Market Players

• Grifols S.A.
• Octapharma AG
• Intas Pharmaceuticals Ltd
• LFB S.A.
• Takeda Pharmaceutical Company Limited
• CSL Limited
• Biotest AG
• Kedrion S.p.A
• Bio Products Laboratory Ltd.
• Bharat Serums and Vaccines Limited

Report Scope

In this report, the Global Plasma Fractionation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Plasma Fractionation Market, By Product:

• Albumin
• Immunoglobulins
• Coagulation Factors
• Protease Inhibitors
• Others

Plasma Fractionation Market, By Application:

• Neurology
• Hematology
• Oncology
• Immunology
• Others

Plasma Fractionation Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Plasma Fractionation Market.

Available Customizations

Global Plasma Fractionation Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Plasma Fractionation Market

5. Global Plasma Fractionation Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Albumin, Immunoglobulins, Coagulation Factors, Protease Inhibitors, Others)
  • 5.2.2. By Application (Neurology, Hematology, Oncology, Immunology, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Plasma Fractionation Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Plasma Fractionation Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
  • 6.3.2. Mexico Plasma Fractionation Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
  • 6.3.3. Canada Plasma Fractionation Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application

7. Europe Plasma Fractionation Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Plasma Fractionation Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
  • 7.3.2. Germany Plasma Fractionation Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Plasma Fractionation Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Plasma Fractionation Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Plasma Fractionation Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application

8. Asia Pacific Plasma Fractionation Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Plasma Fractionation Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
  • 8.3.2. India Plasma Fractionation Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
  • 8.3.3. South Korea Plasma Fractionation Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
  • 8.3.4. Japan Plasma Fractionation Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Plasma Fractionation Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application

9. South America Plasma Fractionation Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Plasma Fractionation Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Plasma Fractionation Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Plasma Fractionation Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application

10. Middle East and Africa Plasma Fractionation Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Plasma Fractionation Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Plasma Fractionation Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Plasma Fractionation Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions : Conflicts, Pandemics and Trade Barriers

14. Global Plasma Fractionation Market: SWOT Analysis

15. Porters Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Products

16. Competitive Landscape

• 16.1. Grifols S.A.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. Octapharma AG
• 16.3. Intas Pharmaceuticals Ltd
• 16.4. LFB S.A.
• 16.5. Takeda Pharmaceutical Company Limited
• 16.6. CSL Limited
• 16.7. Biotest AG
• 16.8. Kedrion S.p.A
• 16.9. Bio Products Laboratory Ltd.
• 16.10. Bharat Serums and Vaccines Limited

17. Strategic Recommendations

18. About Us & Disclaimer